Abstract:350 Purpose: CD38 showed strongly over-expression in several kinds of lymphoma, especially for multiple myeloma (MM). Daratumumab is a FDA-approved CD38 specific monoclonal human antibody, which could be used for immunoPET imaging after radiolabeling. However, the intact antibody usually has a long blood circulation and late uptake peak in target. Therefore, this study used the F(ab’)2 fragments of daratumumab to visualize CD38 in a CD38-positive lymphoma model. Methods: F(ab’)2 fragments of daratumumab were prepared using IdeS enzyme and purified with Protein A beads. They were further tested by HPLC and gel electrophoresis. After conjugated with p-SCN-Bn-NOTA (NOTA), the fragments were radiolabeled with 64Cu (t1/2 = 12.7 h). F(ab’)2 fragments of human non-specific IgG and the intact antibody daratumumab were used as controls and prepared using the same methods. In vitro, fluorescein dye conjugated daratumumab-F(ab’)2 was used to evaluate the cellular uptake. CD38-positive Ramos cells were implanted subcutaneously to build a lymphoma murine model. Serial small animal PET imaging was performed after injection of 64Cu labeled F(ab’)2-daratumumab, 64Cu labeled F(ab’)2-IgG or intact daratumumab. PET data were analyzed by drawing ROI. Biodistribution study and histological staining were performed at the end of time point. Results: HPLC and SDS-PAGE results showed that the molecular weight of F(ab’)2 fragments was about 110 kDa, suggesting a successful digestion. Fluorescein dye conjugated F(ab’)2-daratumumab bound with cell membrane, observed by microscopy. After conjugated with NOTA, the F(ab’)2 fragments or intact antibody were labeled with 64Cu (labeling yield > 90%). PET imaging showed 64Cu-NOTA-F(ab’)2-daratumumab had a rapid and high tumor uptake as early as 4 h post-injection (8.2 ± 0.9 %ID/g) and reached the peak at 12 h (9.5 ± 0.7 %ID/g) (n = 4). In the comparison, 64Cu-NOTA -F(ab’)2-IgG demonstrated a near-background tumor uptake in Ramos model (no more than 2% at any time point). Both of labeled F(ab’)2 fragments showed the highest uptake in kidneys. Even 64Cu labeled intact antibody showed an increasing tumor uptake (up to 8.3 ± 1.4 %ID/g at 48 h), uptake in the blood pool was still high (6.9 ± 0.8 %ID/g at 48 h), as well as other blood-rich organs. The tumor-to-background ratios of 64Cu-NOTA -F(ab’)2-daratumumab were significantly higher than those of daratumumab after 4 h post injection (P<0.05). 64Cu-NOTA -F(ab’)2-daratumumab showed the highest tumor-to-blood ratio at 18.9 ± 4.6 and tumor-to-muscle ratio at 40.4 ± 1.6 at 48 h, while the ratios of intact antibody were 1.2 ± 0.3 (blood) and 13.1 ± 6.0 (muscle), respectively. Biodistribution results at 48 h post-injection verified the PET imaging results. Finally, immunofluorescent staining confirmed the Ramos tumor showed strong expression of CD38. Conclusions: 64Cu labeled F(ab’)2-daratumumab showed an early and high tumor uptake in CD38-positive lymphoma, along with low background, thus it provides a potential PET imaging agent for better usage in clinic in the future.

Noninvasive Evaluation Of Cd20 Expression Using Cu-64-Labeled F(Ab ')(2) Fragments Of Obinutuzumab In Lymphoma

In Vivo PET Imaging of CD20 Using Cu-64-labeled F(ab)2 Fragment of Obinumumab in Lymphoma Models

Near-infrared fluorescence imaging of non-Hodgkin's lymphoma CD20 expression using Cy7-conjugated obinutuzumab

Evaluation of 64Cu-Labeled New Anti-EGFR Antibody NCAB001 with Intraperitoneal Injection for Early PET Diagnosis of Pancreatic Cancer in Orthotopic Tumor-Xenografted Mice and Nonhuman Primates

64Cu-Labeled F(ab’)2 Fragments of Daratumumab for Early Visualization of CD38-positive Lymphoma

CD19-immunoPET for noninvasive visualization of CD19 expression in B-cell lymphoma patients

Evaluation of a novel monoclonal antibody mAb109 for noninvasive molecular imaging of lung carcinoma

Immuno-PET Imaging of CD93 Expression with 64Cu-Radiolabeled NOTA-mCD93 ([64Cu]cu-Nota-mcd93) and Insulin-Like Growth Factor Binding Protein 7 ([64Cu]cu-Nota-igfbp7)

High Antitumor Activity of Sortase A-generated Anti-Cd20 Antibody Fragment Drug Conjugates

Noninvasive PET imaging of CD38 expression using 89Zr-labeled daratumumab in lymphoma

Positron Emission Tomography Imaging of Tumor Angiogenesis with a (61/64)Cu-Labeled F(ab')(2) Antibody Fragment.

Evaluation of a novel monoclonal antibody mAb109 by immuno-PET/fluorescent imaging for noninvasive lung adenocarcinoma diagnosis

Evaluating 64Cu-DOTA-rituximab as a PET agent in patients with B-cell lymphoma: a head-to-head comparison with 18F-fluorodeoxyglucose PET/computed tomography

ImmunoPET imaging of human CD8+ T cells with novel 68Ga-labeled nanobody companion diagnostic agents

ImmunoPET imaging of CD38 in murine lymphoma models using 89 Zr-labeled daratumumab

Synthesis and evaluation of 64 Cu-radiolabeled NOTA-cetuximab ( 64 Cu-NOTA-C225) for immuno-PET imaging of EGFR expression.

Improved Characteristics of RANKL Immuno-PET Imaging Using Radiolabeled Antibody Fab Fragments

ImmunoPET Imaging of CD146 in Murine Models of Intrapulmonary Metastasis of Non-Small Cell Lung Cancer

64 Cu-labeled daratumumab F(ab′) 2 fragment enables early visualization of CD38-positive lymphoma

ImmunoPET of CD146 in Orthotopic and Metastatic Breast Cancer Models.

Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors